Business
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pa...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico\nMONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI® (tafasitamab), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one prior line of systemic therapy. Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ: INCY) in September 2021 for tafasitamab (commercialized as MONJUVI® (tafasitamab-cxix) in the United States and MINJUVI® ex-USA) across Latin America. Knight has launched MINJUVI® in Brazil, Mexico and Argentina for use in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT). In March 2026, Knight announced the approval and launch of MINJUVI® in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory FL in Brazil.1 “In past two years we have launched MINJUVI® for the treatment of diffuse large B-cell lymphoma in Brazil, Mexico, and Argentina. More recently, MINJUVI® received regulatory approval for the treatment of refractory follicular lymphoma in Brazil,” said Samira Sakhia President and Chief Executive Officer of Knight Therapeutics. “We continue to advance our pipeline with the submissions for MINJUVI® in both Argentina and Mexico. More importantly, MINJUVI® is more than a single product. With approvals across distinct indications, it effectively represents multiple therapies within one brand, expanding the ways physicians can use MINJUVI® to address different patient...